A comparison of the fixed dose combinations of prostaglandin / timolol in the treatment of open angle glaucoma and ocular hypertension has been published recently
Jouni Vuorinen (jouni.vuorinen4pharma.com), Sep 12th 2014A study titled ‘Fixed Dose Combination of Tafluprost and Timolol in the Treatment of Open Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed Combination Products’ by Holló et al. has been published in a recent issue of Advances in Therapy: September 2014, Volume 31, Issue 9, pp 932-944.
The authors introduce current evidence from double-masked trials on the efficacy and safety of prostaglandin/ timolol fixed dose combinations (PTFCs), a popular class of antiglaucoma medications. The medication highlighted in the paper is preservative-free tafluprost/timolol PTFC (TAF/TIM). The paper reviews, summarizes, and compares TAF/TIM response to treatment with those of the brand name PTFCs (Xalacom®, DuoTrav® and Ganfort®).
Specifically, “the four PTFCs yielded a similar reduction in IOP of approximately 32–36% from an untreated baseline IOP of around 24–29 mmHg. A further look on TAF/TIM studies indicated that IOP reductions of up to 40% and beyond could be achieved for untreated baseline pressures of 31 mmHg or higher. Least side effects occurred during treatment with TAF/TIM and Xalacom®. Of these two, only TAF/TIM is preservative- free. Although preservatives may cause ocular surface problems, preservative-free Ganfort® did not cause less hyperemia or irritation than the preserved preparation indicating that these side effects are associated with an inherent property of bimatoprost.”
The publication undoubtedly facilitates a better understanding of available options in view of the imminent launch of the recently developed TAF/TIM (TAPTIQOM®). The therapeutic review with a careful methodological comparison is of significant use, since clinicians and patients must choose between the medications, and efficacy and side effect profiles are essential for this decision process.